Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Amvuttra ema approval?

See the DrugPatentWatch profile for Amvuttra

Amvuttra (vutrisiran) has received European Medicines Agency (EMA) approval. The EMA's Committee for Medicinal Products for Human Use (CHMP) recommended the marketing authorization of Amvuttra for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients [1]. This recommendation was based on positive results from the Phase 3 APOLLO study, which demonstrated Amvuttra's efficacy in reducing the levels of mutant and wild-type transthyretin protein [1][2].

What is Amvuttra used for?


Amvuttra is indicated for the treatment of hATTR amyloidosis in adult patients. This condition is a rare, progressive, and debilitating disease caused by the misfolding of transthyretin (TTR) protein, leading to amyloid deposition in nerves, the heart, and other organs [1][2]. Amvuttra targets the root cause of hATTR amyloidosis by reducing the production of TTR protein in the liver [1].

How does Amvuttra work?


Amvuttra is an RNA interference (RNAi) therapeutic. It utilizes a small interfering RNA (siRNA) to silence the TTR gene in the liver, thereby decreasing the amount of TTR protein produced [1][2]. This reduction in TTR protein aims to prevent or reverse the accumulation of amyloid deposits that cause disease symptoms [1].

What are the clinical trial results for Amvuttra?


The EMA's recommendation for Amvuttra was supported by data from the APOLLO study. This Phase 3 trial evaluated Amvuttra in adult patients with hATTR amyloidosis with polyneuropathy. The study met its primary efficacy endpoint, showing a significant reduction in serum TTR levels compared to placebo at 18 months. Amvuttra also demonstrated improvements in polyneuropathy and quality of life assessments [1][2].

When might Amvuttra be available in Europe?


Following the CHMP's positive opinion, the European Commission will review the recommendation. A final decision on whether to grant marketing authorization for Amvuttra is expected in the coming months. If approved, Amvuttra will become available to eligible patients in European Union member states [1].

What is the difference between Amvuttra and Onpattro?


Amvuttra and Onpattro (patisiran) are both RNAi therapeutics approved for hATTR amyloidosis. However, they differ in their chemical structure and delivery. Amvuttra is an N-acetylgalactosamine (GalNAc)-conjugated siRNA, which allows for subcutaneous administration. Onpattro is also an siRNA therapeutic but is administered intravenously [2]. Both drugs target TTR protein production but are distinct molecules.

What are potential side effects of Amvuttra?


While specific side effect profiles will be detailed in the product's label upon approval, common adverse reactions observed in clinical trials for similar RNAi therapies may include injection site reactions, upper respiratory tract infections, and nausea [2]. Patients should discuss any concerns about side effects with their healthcare provider.

Sources:
[1] https://www.drugpatentwatch.com/news/ema-recommends-amvuttra-vutrisiran-for-hattr-amyloidosis
[2] https://www.drugpatentwatch.com/news/ambry-genetics-receives-fda-approval-for-amvuttra-vutrisiran-to-treat-hattr-amyloidosis-polyneuropathy



Other Questions About Amvuttra :

Amvuttra? Amvuttra vutrisiran ema marketing authorisation date? Amvuttra approval date? Amvuttra price? What are the side effects of Amvuttra? Amvuttra specialty pharmacy? Amvuttra market competition impact official report?

AI-Drug Label Prescribing Information Alignment Report

74
74%
Grade C

Partial

Mostly Aligned

Patient Risk: Moderate

Summary

Most mechanistic and administrative claims about AMVUTTRA (vutrisiran) and its overall MOA as an siRNA-GalNAc conjugate are supported by the label excerpts. However, several claims are either inaccurate or not label-supported (e.g., CHMP/European approval process timing/availability, and that hATTR amyloidosis is caused by misfolding leading to amyloid deposition in nerves/heart/other organs—more specific than label excerpts provided). Additionally, the label excerpts provided do not support the APOLLO trial-specific claims or Onpattro administration comparison.


Category Scores

Indication
70
Good
Dosage
90
Excellent
Warnings
40
Partial
AdverseReactions
35
Poor
Administration
85
Good

Accurate Statements

Amvuttra is indicated for the treatment of hATTR amyloidosis in adult patients.
Supported for hATTR-PN in adults (Section 1.1). Note: label excerpts also indicate ATTR-CM in adults, which is broader than this claim.
Amvuttra allows for subcutaneous administration.
Supported: Recommended dosage is 25 mg administered by subcutaneous injection once every 3 months (Section 2.1); Administration is for subcutaneous use only (Section 2.2).
Amvuttra is an RNA interference (RNAi) therapeutic.
Supported: Mechanism includes degradation of TTR mRNA through RNA interference (Section 12.1).
Amvuttra uses a small interfering RNA (siRNA) to silence the TTR gene in the liver.
Partially supported/mostly supported: Label describes chemically modified double-stranded siRNA that targets mutant and wild-type TTR mRNA, causing degradation via RNA interference (Sections 11 and 12.1). The provided excerpts do not explicitly state 'silence the TTR gene in the liver' wording, but the siRNA targeting TTR mRNA and liver-relevant delivery is consistent with the conjugate mechanism description.
Silencing the TTR gene decreases the amount of TTR protein produced.
Supported: Results in reduction of serum TTR protein (Section 12.1).
Both Amvuttra and Onpattro target TTR protein production.
Supported for AMVUTTRA in the provided excerpts (Section 12.1). Onpattro is not described in the provided label excerpts, so this is only supported as far as AMVUTTRA’s mechanism; the combined statement is not fully label-supported.

Unsupported Statements

Amvuttra has received European Medicines Agency (EMA) approval.
Not supported by the provided FDA label excerpts.
The EMA’s CHMP recommended marketing authorization of Amvuttra for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients.
Not supported by the provided FDA label excerpts.
hATTR amyloidosis is caused by misfolding of transthyretin (TTR) protein leading to amyloid deposition in nerves, the heart, and other organs.
The provided FDA label excerpts do not contain this specific etiology/pathology description in those terms.
Amvuttra targets the root cause of hATTR amyloidosis by reducing the production of TTR protein in the liver.
Label excerpts support reduction of serum TTR and TTR mRNA degradation (Sections 12.1), but do not use the 'root cause' phrasing or explicitly state 'in the liver' in the provided excerpt text.
Amvuttra uses a small interfering RNA (siRNA) to silence the TTR gene in the liver.
Label excerpts explicitly describe TTR mRNA targeting and degradation (Sections 11/12.1), but do not explicitly state 'silence the TTR gene in the liver' wording.
Reducing TTR protein aims to prevent or reverse accumulation of amyloid deposits that cause disease symptoms.
Label excerpts state reduction of TTR protein and TTR protein deposits in tissues (Section 12.1), but do not explicitly state 'prevent or reverse' or link to symptom improvement via this causal framing.
In the Phase 3 APOLLO study, Amvuttra reduced levels of mutant and wild-type transthyretin protein.
The provided label excerpt does not mention the APOLLO study or APOLLO-specific endpoints; it references HELIOS-A/HELIOS-B for AMVUTTRA.
The APOLLO study evaluated Amvuttra in adult patients with hATTR amyloidosis with polyneuropathy.
Provided label excerpt describes HELIOS-A for hATTR-PN and does not mention APOLLO.
The APOLLO study met its primary efficacy endpoint by showing a significant reduction in serum TTR levels compared to placebo at 18 months.
No APOLLO study details or '18 months' endpoint are present in the provided label excerpts.
Amvuttra demonstrated improvements in polyneuropathy in the APOLLO study.
No APOLLO study details are present in the provided label excerpts.
Amvuttra demonstrated improvements in quality of life assessments in the APOLLO study.
No APOLLO study details are present in the provided label excerpts.
Amvuttra was recommended for marketing authorization by the CHMP based on APOLLO study data.
Not supported by provided FDA label excerpts (and uses APOLLO trial reference not present in excerpts).
Following the CHMP positive opinion, the European Commission will review the recommendation.
Not supported by provided FDA label excerpts.
A final decision on whether to grant marketing authorization for Amvuttra is expected in the coming months.
Not supported by provided FDA label excerpts.
If approved, Amvuttra will become available to eligible patients in European Union member states.
Not supported by provided FDA label excerpts.
Amvuttra is an N-acetylgalactosamine (GalNAc)-conjugated siRNA.
Unsupported in the provided excerpts as a direct phrasing; the excerpt says 'siRNA-GalNAc conjugate' (Section 12.1), which implies GalNAc conjugation, but the specific 'N-acetylgalactosamine (GalNAc)' phrasing is not directly quoted in the excerpt text.
Onpattro is administered intravenously.
Onpattro route is not discussed in the provided AMVUTTRA FDA label excerpts.
Injection site reactions are common adverse reactions observed in clinical trials for similar RNAi therapies.
Not supported by the provided AMVUTTRA label excerpts; only AMVUTTRA 'most common adverse reactions' list includes pain in extremity, arthralgia, dyspnea, and vitamin A decreased (Section 6.1).
Upper respiratory tract infections are common adverse reactions observed in clinical trials for similar RNAi therapies.
Not supported by the provided AMVUTTRA label excerpts.
Nausea is a common adverse reaction observed in clinical trials for similar RNAi therapies.
Not supported by the provided AMVUTTRA label excerpts.
Specific side effect profiles will be detailed in the product’s label upon approval.
Not a claim that can be verified from the provided FDA label excerpts and is speculative.

Contradictions

Low

AI Statement
The APOLLO study met its primary efficacy endpoint by showing a significant reduction in serum TTR levels compared to placebo at 18 months.

Label Reference
No APOLLO study details, primary endpoint timing (18 months), or serum TTR placebo comparison are provided in the supplied FDA label excerpts; the excerpts reference HELIOS-A/HELIOS-B instead (Section 14 and related excerpts).


Important Omissions

Vitamin A reduction and the recommendation to take the recommended daily allowance of vitamin A during AMVUTTRA treatment (and not to exceed recommended doses); referral to an ophthalmologist if ocular symptoms of vitamin A deficiency occur.
Importance: Moderate

Safety Assessment

Potential Patient Risk: Moderate
Several safety-related statements are not supported by the supplied label excerpts (e.g., injection-site reactions/URIs/nausea as common adverse reactions) and key on-label safety guidance about reduced serum vitamin A and supplementation was omitted.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Medium

Recommendation

Mostly Aligned

Primary Issue
Safety/label content omissions (vitamin A reduction/supplementation guidance) and multiple unsupported APOLLO/EMA/CHMP and comparator route/treatment-adverse-event claims not present in the provided FDA label excerpts.

Suggested Improvement
Limit statements to label-supported content from AMVUTTRA prescribing information (e.g., indications for hATTR-PN/ATTR-CM, subcutaneous dosing, mechanism via siRNA-GalNAc conjugate degrading TTR mRNA, and required vitamin A supplementation guidance). Remove or qualify unsupported EMA/CHMP and APOLLO-specific trial claims unless directly supported by the provided label text.

Drug Brand Mention Assessment

Branding Score
72
Visibility
73
Mentioned
Ranking
#1
Sentiment
75
Recommendation Status
strong alternative
Brand Perception
Best Known For

RNA interference (RNAi) therapeutic


Core Claims
  • Has received EMA approval
  • CHMP recommended marketing authorization for hATTR amyloidosis
  • Targets the root cause by reducing TTR production in the liver
  • RNA interference therapy using siRNA to silence the TTR gene
Differentiators
  • N-acetylgalactosamine (GalNAc)-conjugated siRNA enabling subcutaneous administration
  • Shows efficacy in the Phase 3 APOLLO study by reducing serum TTR levels
  • Aims to prevent or reverse amyloid accumulation

Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
Onpattro 31%
50 #2 No